Ovarian Cancer and Us - best viewed in FIREFOX

Google Search: this blog, links from posts and the web.....

Loading...

Wednesday, March 09, 2011

Linus Pauling Institute at Oregon State University (research institute vitamins/micronutriends/phytochemicals)



Researchers at the Linus Pauling Institute investigate the role that vitamins and essential minerals (micronutrients) and chemicals from plants (phytochemicals) play in human aging, immune function, and chronic diseases, especially heart disease, cancer, and neurodegenerative diseases. A major emphasis is to understand the role of oxidative stress and inflammation in disease etiology, and the preventive effects of dietary constituents with antioxidant or anti-inflammatory properties.
The goal of these studies is to understand the mechanisms by which diet, micronutrients, and dietary supplements affect disease initiation and progression and can be used in the prevention or treatment of human diseases, thereby enhancing lifespan and healthspan......cont'd


NIH/NCCAM
Center of Excellence

The Linus Pauling Institute is one of the nation's first two Centers of Excellence for Research on Complementary and Alternative Medicine designated by the National Center for Complementary and Alternative Medicine (NCCAM) of the National Institutes of Health (NIH).

ELC : Imedex e-learning center March 8th, 2011 video (30 min) interviews from SGO



Note: requires password/registration to view videos (free), risk factors, hereditary, KRAS mutation/variant (in many other cancers as well), MiRnA, ICON7 (Avastin).....    

Featured Activity:


Best of the Day: 2011 Society of Gynecologic Oncologists Annual Meeting on Women’s Cancer

Dr Bradley Monk interviews 6 nationally recognized experts in GYN oncology about their interpretations of clinically relevant data presented at the annual meeting. Drs Deborah Armstrong, Barbara Goff, Tom Herzog, Warner Huh, Robert Coleman, and Robert Burger comprise the esteemed faculty.

update on ovariancancerandus blog stats - just for fun



Pageviews today:  323

Pageviews yesterday:  323

Pageviews last month:  8,231



by Country in order of most popular (top 10)

U.S.
Canada
Italy
Germany
UK
Hungary
Vietnam
Russia
United Arab Emirates
China

Genetic Tests Sold Direct To Consumers Should Be Supervised By Doctors Says FDA Panel (and the debating issues)




A First Medical Opinion Can Influence The Second - Medical News Today




Dr Henry Lynch, Sr (Lynch Syndrome) - Omaha doctor pioneered genetic cancer concept - LivewellNebraska.com




Conflicts-of-interest in drug studies sneaking back into medical journals, say investigators Jewish General/McGill - press release




2011 journal issues - current content listings Jan/March 2011 including supplement (SGO meeting)



You are not entitled to access the full text of this document Articles in Press
CloseVolume 120 (2011)
You are not entitled to access the full text of this documentVolume 120, Issue 3 - selected
pp. 317-492 (March 2011)
Technologic Innovations and Novel Surgical Approaches for Patients with Gynecologic Malignancies
You are not entitled to access the full text of this documentVolume 120, Issue 2
pp. 165-316 (February 2011)
You are entitled to access the full text of this documentVolume 120, Issue 1
pp. 1-164 (January 2011)
You are not entitled to access the full text of this documentVolume 120, Supplement 1
pp. S1-S150 (March 2011)
ABSTRACTS PRESENTED FOR THE 42ND ANNUAL MEETING OF THE SOCIETY OF GYNECOLOGIC ONCOLOGISTS, ABSTRACTS PRESENTED FOR THE 42ND ANNUAL MEETING OF THE SOCIETY OF GYNECOLOGIC ONCOLOGISTS

abstracts/index - Gynecologic Oncology, Volume 120, Issue 3, Pages 317-492 (March 2011)




abstract: A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: (GOG 146Q)



Journal Gynecologic Oncology, Volume 120, Supplement 1, Pages S1-S150 (March 2011) abstracts to be presented at 2011 annual SGO meeting



Note: this journal is by subscription ($$$) for full access, the actual abstracts via this indexed list are not available - titles of presentations only - abstracts either have been previously published or to come


Volume 120, Supplement 1, Pages S1-S150 (March 2011)

ABSTRACTS PRESENTED FOR THE 42ND ANNUAL MEETING OF THE SOCIETY OF GYNECOLOGIC ONCOLOGISTS
Orlando, FL USA
March 2011

Ovarian cancer: early detection saves lives | McGill University (Montreal) Health Centre - the Dove Project



For more information about DOVE: http://muhc.ca/royalvic/article/dove-project

financial news: Healthcare Stock on Watch; Vermillion (OVA1) climbs on Poster Presentation | Beacon Equity: Penny Stocks, Stock Alerts



Healthcare Stock on Watch; Vermillion climbs on Poster Presentation

Vermillion Inc. (NASDAQ: VRML) shares are up nearly 2.5% to $4.99 mid-day on word of the company’s poster presentation of its preliminary results from its collaboration with John Hopkins University School of Medicine to identify biomarkers that improve the identification of malignant ovarian tumors.
The poster evaluated more than 20 candidate biomarkers for their ability to complement the company’s CA125 in distinguishing benign ovarian tumors from malignant ones.


Medical News: Bevacizumab Value in Ovarian Cancer Questioned - in Clinical Context, Ovarian Cancer from MedPage Today



Note: the actual study including those related to Avastin/breast cancer were previously posted (on this blog) but this particular Medscape article may be easier to read.
Search blog (top left hand column or sidebar) via key word Avastin.

NCI Cancer Bulletin Mar 2011: Ovarian Cancer Study Raises Questions about Developing Markers for Early Detection



 IMPORTANT/Blogger's Note:  longterm ovarian cancer survivours and caregivers will recall the historical 'hype' on new early detection tests - caution advised and confirming this as per the NCI Bulletin below (LPA would be one example only)


"During the last decade, Dr. Ransohoff noted, some researchers made strong claims about potential markers for ovarian cancer based on preliminary data. And though the markers did not pan out, these claims were repeated by members of the media, raising false hopes about early detection."



"A long-awaited assessment of potential biomarkers for detecting early ovarian cancer shows that blood levels of the CA-125 protein remain the best predictor of the disease. But if there is to be any hope that screening will reduce deaths from this disease, then more accurate markers would have to be developed, researchers concluded in the March Cancer Prevention Research.         (note: also see blog postings for related abstracts)

None of the 28 potential serum markers tested in the study outperformed CA-125. But for screening, the researchers noted, doctors would need a test that could detect a signal from tumors more than 6 months before diagnosis; CA-125 had its strongest signal within 6 months of diagnosis.

Although the results may seem disappointing, the findings can inform future efforts to detect the disease early, the study authors wrote. This idea was echoed by several biomarker experts who were not involved in the work but who stressed the importance of the findings......."cont'd

2011 March Cancer Prevention Research articles/references: Ovarian Cancer Biomarker Performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Specimens — Cancer Prev Res



Ovarian Cancer Biomarker Performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Specimens

Articles citing this article